Redhill Biopharma (STU:2RH0) Common Stock : €4.26 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Common Stock?

Redhill Biopharma's quarterly common stock declined from Dec. 2022 (€2.68 Mil) to Mar. 2023 (€2.66 Mil) but then increased from Mar. 2023 (€2.66 Mil) to Jun. 2023 (€4.26 Mil).

Redhill Biopharma's annual common stock increased from Dec. 2021 (€1.32 Mil) to Dec. 2022 (€2.68 Mil) and increased from Dec. 2022 (€2.68 Mil) to Dec. 2023 (€19.66 Mil).

Redhill Biopharma Common Stock Historical Data

The historical data trend for Redhill Biopharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Common Stock Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.87

1.32

2.68

19.66

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															1.85	2.68	2.66	4.26	19.66

Redhill Biopharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Redhill Biopharma (STU:2RH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines